Latest news with #CDD
NZ Herald
6 days ago
- Health
- NZ Herald
Rare disorders: Waikato toddler's journey to rare and severe CDD diagnosis
A 2-year-old Waikato girl was having around 30 seizures daily before being diagnosed with a rare condition, her mum said. Mila Smith, of Hamilton, has CDKL5 deficiency disorder (CDD), a severe developmental epileptic encephalopathy, caused by mutations in the CDKL5 gene. CDD leads to early-onset and drug-resistant seizures and
Jordan Times
04-05-2025
- Business
- Jordan Times
Kingdom's corporate registrations rise by 13% in first third of 2025
A total of 2,372 new companies are registered, compared with 2,091 during the January-April in 2024 (Petra photo) AMMAN — New registered companies increased by 13 per cent during the first four months of 2025, compared with the same period in 2024, the Companies Control Department (CCD) said on Sunday. The CDD said that 2,372 new companies were registered in the January-April period of 2025, compared with 2,091 during the corresponding period of 2024, the Jordan News Agency, Petra, reported. According to the CDD, the total registered capital during the same period exceeded JD66 million. Recording the highest number, a total of 1,723 limited liability companies (LLCs) were registered, constituting 72.6 per cent of the overall figure, with capital exceeding JD36 million. The data also recorded a 49 per cent drop in the number of company dissolutions and deregistration during the first third of the year, compared with 2024. A total of 376 companies were de-registered or dissolved, compared with 741 during the same period last year. The CCD figures revealed that capital increases surged by 518 per cent, against the same period in 2024, reaching around JD590 million, compared with around JD145 million in 2024. Meanwhile, 624 companies increased their capital by some JD617 million, while 97 others lowered their capital by JD79 million.
Khaleej Times
29-04-2025
- Health
- Khaleej Times
Oxford-Harrington Rare Disease Centre appoints Majid Jafar to its advisory council
The Oxford-Harrington Rare Disease Centre ('OHC'), a partnership between the University of Oxford, UK and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio, aimed at driving cutting-edge rare disease breakthroughs, has announced the appointment of Majid Jafar to its Advisory Council. The Advisory Council, led by former UK Prime Minister David Cameron, supports the OHC's mission to deliver new treatments for the nearly half a billion people affected by rare diseases worldwide. Council members are leaders of relevant industries and sectors, from different regions of the world who bring expertise, resources and networks towards the initial goal of developing 40 new drugs for rare diseases in the next 10 years. Jafar is a distinguished business leader serving as Vice-Chairman of the Crescent Group and CEO of Crescent Petroleum, based in the United Arab Emirates, and is the first person to be appointed to the Council from the GCC and Middle East, a region with over 30 million people affected by rare diseases. He is a prominent, global rare disease advocate and philanthropist with a strong commitment to driving positive social change in healthcare and education, with extensive networks and interests in business, investment and philanthropy in the US, Europe and the Middle East. Among his roles, Mr. Jafar is the co-founder, with his wife Lynn, of the Loulou Foundation, a private non-profit foundation dedicated to advancing science and treatments for CDKL5 Deficiency Disorder (CDD), a rare neurogenetic disorder that affects their eldest daughter, Alia. The Loulou Foundation has funded important research projects at leading universities and institutions in the US, Europe and Asia, with a total of over 60 projects at 45 different institutions. Jafar also sits on various non-profit boards including the Board of Fellows of Harvard Medical School, where he co-chairs the Discovery Council, and is a member of the Academy of the University of Pennsylvania and the Global Precision Medicine Council of the World Economic Forum, as well as co-chairing the campaign for Cambridge Children's Hospital in the UK. David Cameron, Chair of the OHC's Advisory Council, said: 'We are delighted to welcome Majid to the OHC Advisory Council. His extensive experience within the business and investment communities and in policy engagement - alongside his philanthropic efforts in education and healthcare - make him an invaluable addition to our team. Furthermore, as a parent of a child with a rare disease, Majid has a deep empathy with families in similar situations as they seek a diagnosis and treatment. We look forward to his contribution to the Council and to his support of the OHC as it continues its groundbreaking work in rare disease research and development of new treatments for patients worldwide.' Majid Jafar commented: 'I am honoured to join the Oxford-Harrington Rare Disease Centre Advisory Council. Supporting the development of innovative treatments for rare diseases is a cause close to my heart with my family's own experience deeply shaping my commitment to delivering urgently needed treatments to rare disease patients. I look forward to helping advance the OHC's mission by fostering key partnerships in new regions and sourcing philanthropic investment that can accelerate progress for the many patients in need.' Matthew Wood, Director and Chief Scientific Officer of the OHC, added: 'Majid brings a unique perspective to our Advisory Council, with his strong leadership background and dedication to advancing healthcare. His commitment to social impact, coupled with his ability to expand the OHC's reach into new regions, will be instrumental as we work towards delivering rare disease drugs in the coming years. We are thrilled to have him on board and look forward to his contributions to our mission.' Majid Jafar joins Lord Cameron (Chair of the OHC's Advisory Council and Former UK Prime Minister), Professor Sir John Bell (President, Ellison Institute of Technology Oxford, and former Regius Professor of Medicine at Oxford University), Baroness Nicola Blackwood (Chair of Genomics England and of Oxford University Innovation), John F. Crowley (President and CEO of the Biotechnology Innovation Association (BIO)), Ronald G. Harrington (a renowned entrepreneur and philanthropist, and co-founder of Harrington Discovery Institute), and Jonathan S. Stamler, MD (President and co-founder of Harrington Discovery Institute and Distinguished University Professor of Medicine), on the OHC Advisory Council.
Yahoo
24-04-2025
- Health
- Yahoo
$35M UIowa project will raze, move Center for Disabilities and Development. What to know:
Citing outdated conditions at its 1950-era facility and a need to free up space for a new inpatient tower, the Iowa Board of Regents approved the University of Iowa's request to raze and relocate the Center for Disabilities and Development (CDD). The university will enter a 20-year lease at a former office building 15 minutes from the main medical campus to house the many offerings of the CDD. The demolition project is anticipated to begin in late 2026. Renovations at the new building are expected to cost $35 to $40 million. The CDD, built in 1954 at 100 Hawkins Dr., is in the path of the planned new UI Health Care inpatient tower. Ongoing construction, according to board documents, is hampering local clinical services, including the cytogenetics lab and the sleep disorders clinic, making it 'difficult, if not impossible, to continue to occupy the building." The UI also said the 100,500-square-foot building needs 'significant renovations and upgrading' and has "no significant architectural or historic significance.' The building's demolition is expected to eliminate $20 million in deferred maintenance costs. More: Meet the latest nominees for the Iowa City Press-Citizen Student of the Week The CDD serves all 99 of Iowa's counties, and about '70% of CDD's patients come from outside Johnson County.' Services at the CDD center focus on providing diagnostic and therapeutic care for individuals with complex disabilities, addressing a range of medical, physical, and behavioral conditions. The CDD will relocate to a 58,000-square-foot building at 2610 Northgate Dr., Iowa City, near the N Dodge Street Interstate 80 exit and the Highlander Hotel. The lease will last 20 years, anchored by four five-year renewals. 'Moving to this new location will give us the opportunity to create a more innovative and state-of-the-art environment for individuals with disabilities and their families to receive care, as well as conduct research, and lead community engagement efforts and interdisciplinary training,' said Jim Leste, chief administrative officer for UI Health Care Stead Family Children's Hospital in a news release. More: Iowa City again pauses rezoning for apartments on Governor St. amid neighborhood opposition The University and UI Health Care believe that the services offered will be 'more successful' thanks to the new building's "convenient access" to the interstate and additional space. 'This will be a huge benefit for the many patients who travel to us for specialized care from all over the state," Leste said. The CDD's services are not expected to relocate until late 2026 or early 2027 to allow time for necessary renovations at the Northgate facility. The new CDD will include patient clinic rooms, diagnostic and treatment areas, specialized patient rehabilitation spaces, a lab, faculty offices, and nursing/staff support spaces, along with an exterior playground. As part of the lease agreement, the landlord will build a 15,000-25,000 square-foot addition and will be solely responsible for the costs of a new roof, replacing the air handling units, upgrading the surface parking lots, and making other landscaping improvements. More: University of Iowa dean says five student visas have been revoked. What to know: The total estimated cost of the renovations is $35 to $40 million, which UI Health Care will pay for 'upon substantial completion.' The full lease agreement has not been made public. UI Health Care will pay approximately $2.89 per square foot annually for operating and maintenance costs and real estate taxes. Jessica Rish is an entertainment, dining and education reporter for the Iowa City Press-Citizen. She can be reached at JRish@ or on X, formerly known as Twitter, @rishjessica_ This article originally appeared on Iowa City Press-Citizen: UI plans to raze, relocate Center for Disabilities and Development
Associated Press
02-04-2025
- Science
- Associated Press
Collaborative Drug Discovery Integrates CDD Vault with NVIDIA BioNeMo NIM For AlphaFold2 and DiffDock Models
BURLINGAME, CA, UNITED STATES, April 2, 2025 / / -- Collaborative Drug Discovery, Inc. (CDD) announces the integration of NVIDIA BioNeMo NIM microservices for AlphaFold2 and DiffDock models into CDD Vault. This integration enriches experimental data within CDD Vault, a single, intuitive web-based platform, by incorporating predictive, industry-leading models. Researchers can manage, analyze, and securely collaborate on the integrated data with enhanced models, unlocking deeper insights and enabling more informed decision-making. Scientists engaged in both commercial and humanitarian drug discovery have demonstrated that the integration with BioNeMo NIM for AlphaFold2 and DiffDock significantly enhances CDD Vault's existing AI module. These models are a powerful addition to CDD's chemistry-aware bioisosteric generation for novel structures (IP) and ultrafast deep-learning similarity capabilities. Chemists and biologists can now combine the best of their intuition with generative capabilities for small molecules visualized together with biological proteins. NVIDIA NIM is a set of easy-to-use microservices designed to accelerate the deployment of generative AI models across the cloud, data center, and workstations. NIM microservices are categorized by model family and on a per-model basis. 'We wanted to give the 690+ research labs that are using CDD Vault effortless access to the powerful BioNeMo NIM tools, enabling them to seamlessly combine over 4 billion experimental data points and 80 million structures with AI-driven insights from these models,' said CDD Cheminformatician and Research Informatics Senior Scientist Dr. Peter Gedeck. Collaborative Drug Discovery empowers CDD Vault users with access to powerful NVIDIA AI tools, BioNeMo NIM for AlphaFold2, a deep learning model that accelerates protein structure determination, and DiffDock, which predicts the 3D orientation and docking interactions of small molecules with proteins. These advanced tools provide a comprehensive structure-based drug discovery (SBDD) extension, enhancing the traditional capabilities of the CDD Vault scientific informatics platform. 'CDD Vault's strength is biological and chemical activity data management,' said Barry Bunin, CEO and Founder of Collaborative Drug Discovery. 'With our ELN (electronic laboratory notebook), Inventory, Curves, Automation, and AI modules, it was natural for us to collaborate with NVIDIA, the leading company for biological modeling. Our customers, some of whom are already using AlphaFold2 and DiffDock, are excited to have access to the NIM for these models, to support seamlessly integrating with CDD Vault, and more quickly move to deployment.' 'The ability to model biology and generate new chemical structures with AI is a profound breakthrough transforming the healthcare and life sciences space,' said Janet Paulsen, Senior Alliance Manager, Drug Discovery, NVIDIA. 'The integration of NVIDIA BioNeMo NIM microservices into CDD's Vault platform equips researchers on the forefront of this innovation with the advanced AI tools needed to harness data that can unlock biological insights.' About Collaborative Drug Discovery (CDD) CDD's ( flagship product, CDD Vault®, is a premier hosted database solution for the secure management and sharing of biological and chemical research data. CDD Vault® provides tools for managing chemical and biological registrations, structure-activity relationships (SAR), and organizing experiments. The platform's available modules include Registration, Activity, Visualization, Assays, ELN, Inventory, Curves, AI, and Automation. Abraham Wang +1 650 242 5259 Legal Disclaimer:
